Your browser doesn't support javascript.
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov, David; Bolshakova, Maria; Mikhaeilyan, Melania; Trotzky-Sirr, Rebecca.
  • Dadiomov D; University of Southern California School of Pharmacy, 1985 Zonal Ave, Los Angeles, CACA, 90089, USA. dadiomov@usc.edu.
  • Bolshakova M; University of Southern California School of Pharmacy, 1985 Zonal Ave, Los Angeles, CACA, 90089, USA.
  • Mikhaeilyan M; University of Southern California School of Pharmacy, 1985 Zonal Ave, Los Angeles, CACA, 90089, USA.
  • Trotzky-Sirr R; University of Southern California School of Pharmacy, 1985 Zonal Ave, Los Angeles, CACA, 90089, USA.
Harm Reduct J ; 19(1): 69, 2022 06 29.
Article in English | MEDLINE | ID: covidwho-1910329
ABSTRACT

BACKGROUND:

Buprenorphine and naloxone are first-line medications for people who use opioids (PWUO). Buprenorphine can reduce opioid use and cravings, help withdrawal symptoms, and reduce risk of opioid overdose. Naloxone is a life-saving medication that can be administered to reverse an opioid overdose. Despite the utility of these medications, PWUO face barriers to access these medications. Downtown Los Angeles has high rates, and number, of opioid overdoses which could potentially be reduced by increasing distribution of naloxone and buprenorphine. This study aimed to determine the accessibility of these medications in a major urban city by surveying community pharmacies regarding availability of buprenorphine and naloxone, and ability to dispense naloxone without a prescription.

METHODS:

Pharmacies were identified in the Los Angeles downtown area by internet search and consultation with clinicians. Phone calls were made to pharmacies at two separate time points-September 2020 and March 2021 to ask about availability of buprenorphine and naloxone. Results were collected and analyzed to determine percentage of pharmacies that had buprenorphine and/or naloxone in stock, and were able to dispense naloxone without a prescription.

RESULTS:

Out of the 14 pharmacies identified in the downtown LA zip codes, 13 (92.9%) were able to be reached at either time point. The zip code with one of the highest rates of opioid-related overdose deaths did not have any pharmacies in the area. Most of the pharmacies were chain stores (69.2%). Eight of the 13 (61.5%) pharmacies were stocked and prepared to dispense buprenorphine upon receiving a prescription, and an equivalent number was prepared to dispense naloxone upon patient request, even without a naloxone prescription. All of the independent pharmacies did not have either buprenorphine or naloxone available.

CONCLUSIONS:

There is a large gap in care for pharmacies in high overdose urban zip codes to provide access to medications for PWUO. Unavailability of medication at the pharmacy-level may impede PWUO ability to start or maintain pharmacotherapy treatment. Pharmacies should be incentivized to stock buprenorphine and naloxone and encourage training of pharmacists in harm reduction practices for people who use opioids.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacies / Buprenorphine / Drug Overdose / Opiate Overdose / COVID-19 / Opioid-Related Disorders Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Harm Reduct J Year: 2022 Document Type: Article Affiliation country: S12954-022-00651-3

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacies / Buprenorphine / Drug Overdose / Opiate Overdose / COVID-19 / Opioid-Related Disorders Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: Harm Reduct J Year: 2022 Document Type: Article Affiliation country: S12954-022-00651-3